Skip to Content
Is technology key to beating breast cancer? Learn more >

Eribulin Disease Interactions

There are 6 disease interactions with eribulin:

Major

Antineoplastics (Includes Eribulin) ↔ Infections

Severe Potential Hazard, Moderate plausibility

Applies to: Infection - Bacterial/Fungal/Protozoal/Viral

Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression. The use of these drugs may be contraindicated in patients with known infectious diseases. All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy. Close clinical monitoring of hematopoietic function is recommended.

References

  1. "Product Information. Novantrone (mitoxantrone)." Immunex Corporation, Seattle, WA.
  2. "Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company, Indianapolis, IN.
  3. "Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb, Princeton, NJ.
View all 31 references
Moderate

Eribulin (Includes Eribulin) ↔ Cytopenias

Moderate Potential Hazard, Moderate plausibility

Applies to: Neutropenia, Thrombocytopenia

Adverse hematologic effects including neutropenia, and febrile neutropenia (fever >=38.5°C with Grade 3 or 4 neutropenia) have been associated with the use of eribulin. It is recommended to monitor complete blood counts prior to each dose and increase the frequency of monitoring in patients who develop Grade 3 or 4 cytopenias. Delay administration of therapy and reduce subsequent doses in patients who experience febrile neutropenia or Grade 4 neutropenia lasting longer than 7 days. Do not administer therapy on Day 1 or Day 8 if ANC < 1,000/mm3, platelets < 75,000/mm3, or grade 3 or 4 non-hematological toxicities.

Moderate

Eribulin (Includes Eribulin) ↔ Hepatic Impairment

Moderate Potential Hazard, Moderate plausibility

Applies to: Liver Disease

Pharmacokinetics studies to evaluate the effect of hepatic impairment in patients treated with eribulin demonstrated that patients with mild hepatic impairment (Child-Pugh A) and moderate hepatic impairment (Child-Pugh B) had higher eribulin exposures as compared to patients with normal hepatic function. It is recommended to reduce the starting dose of eribulin in patients with mild or moderate hepatic impairment according to the manufacturer recommendations. Eribulin has not been studied in patients with severe hepatic impairment (Child-Pugh C). Caution and close monitoring should be taken.

Moderate

Eribulin (Includes Eribulin) ↔ Peripheral Neuropathy

Moderate Potential Hazard, Moderate plausibility

Applies to: Peripheral Neuropathy

In clinical trials, eribulin caused peripheral neuropathy. Monitor patients closely for signs of peripheral motor and sensory neuropathy. It is recommended to withhold treatment in patients who experience Grade 3 or 4 peripheral neuropathy, until resolution to Grade 2 or less.

Moderate

Eribulin (Includes Eribulin) ↔ Qt Prolongation

Moderate Potential Hazard, Moderate plausibility

Applies to: Hypokalemia, Magnesium Imbalance, Electrolyte Abnormalities, Congestive Heart Failure, Arrhythmias, Long QT Syndrome

In clinical trials, eribulin has caused QT prolongation independent of concentration. Close monitoring should be exercised in patients with congestive heart failure, bradyarrhythmias, those taking drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics, and electrolyte abnormalities. It is recommended to correct hypokalemia or hypomagnesemia prior to starting therapy and monitor these electrolytes periodically during therapy. Avoid in patients with congenital long QT syndrome.

Moderate

Eribulin (Includes Eribulin) ↔ Renal Impairment

Moderate Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction

Pharmacokinetics studies to evaluate the effect of renal impairment in patients treated with eribulin demonstrated that patients with moderate and severe renal impairment had higher eribulin dose-normalized exposures compared to that in patients with normal renal function. It is recommended to reduce the starting dose of eribulin in patients with moderate or severe renal impairment (CrCL 15-49 mL/min) according to the manufacturer recommendations.

eribulin drug Interactions

There are 452 drug interactions with eribulin

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2017 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide